Go Pro
→ Washington Is Broke—Could YOUR Savings Be Next? (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$5.78
-2.7%		$5.41
$1.90
▼
$10.59
$8.68M3.068,895 shs2,717 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.47
+0.3%		$0.35
$0.23
▼
$2.75
$9.20M0.972.06 million shs672,104 shs
NRIFF
Nuvo Pharmaceuticals
$0.00
$0.30
▼
$0.87
$8.52M1.577,337 shs3,000 shs
Oragenics, Inc. stock logo
OGEN
Oragenics
$0.52
-1.4%		$0.54
$0.48
▼
$1.45
$2.36M1.2534,509 shs4,703 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-2.69%-3.83%+12.67%+22.46%-11.55%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+0.30%+7.14%+10.20%+80.04%-77.62%
NRIFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Oragenics, Inc. stock logo
OGEN
Oragenics
-0.96%+1.76%-6.02%-17.20%-55.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$5.78
-2.7%		$5.41
$1.90
▼
$10.59
$8.68M3.068,895 shs2,717 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.47
+0.3%		$0.35
$0.23
▼
$2.75
$9.20M0.972.06 million shs672,104 shs
NRIFF
Nuvo Pharmaceuticals
$0.00
$0.30
▼
$0.87
$8.52M1.577,337 shs3,000 shs
Oragenics, Inc. stock logo
OGEN
Oragenics
$0.52
-1.4%		$0.54
$0.48
▼
$1.45
$2.36M1.2534,509 shs4,703 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-2.69%-3.83%+12.67%+22.46%-11.55%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+0.30%+7.14%+10.20%+80.04%-77.62%
NRIFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Oragenics, Inc. stock logo
OGEN
Oragenics
-0.96%+1.76%-6.02%-17.20%-55.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.00
Hold$20.00246.02% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
NRIFF
Nuvo Pharmaceuticals
0.00
N/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OGEN, CNSP, ENSC, and NRIFF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$7.29 per shareN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M1.82N/AN/A$0.63 per share0.75
NRIFF
Nuvo Pharmaceuticals
$52.41M0.00N/A0.82$1.59 per share0.00
Oragenics, Inc. stock logo
OGEN
Oragenics
$40K58.07N/AN/A$1.94 per share0.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$15.85M-$23.59N/AN/AN/AN/A-204.25%-141.87%11/18/2026 (Estimated)
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$2.76N/AN/AN/A-280.53%-2,550.30%-320.49%11/13/2026 (Estimated)
NRIFF
Nuvo Pharmaceuticals
$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/A
Oragenics, Inc. stock logo
OGEN
Oragenics
-$9.84M-$21.42N/AN/AN/AN/A-144.22%-112.79%N/A

Latest OGEN, CNSP, ENSC, and NRIFF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.20-$0.20N/A-$0.20$1.20 million$1.16 million
8/13/2026Q2 2026
Oragenics, Inc. stock logo
OGEN
Oragenics
N/A-$0.57N/A-$0.57N/AN/A
8/12/2026Q2 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.24-$0.38-$0.14-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
5.86
5.86
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.70
0.70
NRIFF
Nuvo Pharmaceuticals
5.27
2.67
2.11
Oragenics, Inc. stock logo
OGEN
Oragenics
N/A
3.01
3.01

Institutional Ownership

CompanyInstitutional Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
NRIFF
Nuvo Pharmaceuticals
N/A
Oragenics, Inc. stock logo
OGEN
Oragenics
18.71%

Insider Ownership

CompanyInsider Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.82%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
NRIFF
Nuvo Pharmaceuticals
N/A
Oragenics, Inc. stock logo
OGEN
Oragenics
16.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
51.46 million1.43 millionNot Optionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1019.46 million18.91 millionNot Optionable
NRIFF
Nuvo Pharmaceuticals
9911.40 millionN/ANot Optionable
Oragenics, Inc. stock logo
OGEN
Oragenics
54.51 million3.79 millionN/A

Recent News About These Companies

Oragenics (NYSEAMERICAN:OGEN) Stock Price Up 1.4% - Here's What Happened
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30999871
Oragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
August 30, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69442136-oragenics-inc-oragenics-reports-continued-clinical-progress-provides-regulatory-and-nyse-american-listing-update-399.htm
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress
August 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/oragenics-faces-nyse-compliance-challenges-amid-trial-progress?utm_source=marketbeat.com&utm_medium=referral
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status
August 28, 2026  |  quiverquant.comQ
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352888/0/en/oragenics-reports-continued-clinical-progress-provides-regulatory-and-nyse-american-listing-update.html
Oragenics: Q2 Earnings Snapshot
August 14, 2026  |  wtop.comW
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy?
August 12, 2026  |  defenseworld.netD
Oragenics Appoints New Chief Financial Officer and Leader
July 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OGEN/pressreleases/3172047/oragenics-appoints-new-chief-financial-officer-and-leader/
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323198/0/en/oragenics-achieves-full-activation-of-australian-phase-iia-trial-network-all-three-sites-now-enrolling.html
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oragenics-present-sidoti-micro-cap-124500288.html
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297513/0/en/oragenics-to-present-at-sidoti-s-micro-cap-virtual-investor-conference-may-20-21.html
ORAGENICS PROVIDES INVESTOR UPDATE
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296615/0/en/oragenics-provides-investor-update.html
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290005/0/en/oragenics-signs-letter-of-intent-to-license-cardiodialysis-technology-from-sigyn-therapeutics-to-target-tbi-induced-systemic-inflammation.html
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287664/0/en/oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury.html
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oragenics-reports-8-study-drug-130000010.html
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
April 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/13/3272489/0/en/oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury.html
Oragenics, Inc. Receives Unqualified Audit Opinion with Going Concern Explanatory Paragraph in Latest Annual Report
March 25, 2026  |  quiverquant.comQ
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
March 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/25/3262664/0/en/oragenics-inc-receives-audit-opinion-with-going-concern-explanation.html
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
March 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/oragenics-files-annual-report-form-123000215.html
Oragenics, Inc.: Oragenics Initiates Phase Iia Clinical Trial Site Activation
March 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67927195-oragenics-inc-oragenics-initiates-phase-iia-clinical-trial-site-activation-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
A white industrial container unit with the Plug logo stands outdoors near piping and storage tanks.
Plug Power Charges Ahead: Margin Expansion Sparks a Rally
By Jeffrey Neal Johnson | August 13, 2026
CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$5.78 -0.16 (-2.69%)
Closing price 09/9/2026 03:48 PM Eastern
Extended Trading
$5.77 -0.01 (-0.17%)
As of 08:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.47 +0.00 (+0.30%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$0.47 -0.01 (-1.77%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Nuvo Pharmaceuticals OTCMKTS:NRIFF

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Oragenics stock logo

Oragenics NYSEAMERICAN:OGEN

$0.52 -0.01 (-1.40%)
Closing price 09/9/2026 04:10 PM Eastern
Extended Trading
$0.51 0.00 (-0.19%)
As of 07:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas